Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Bill Roth
Advertisement
Bill Roth, SVP of Consulting and Advisory, IntegriChain.
Articles by Bill Roth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5